SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A-1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
JULY 19, 2004
GenoMed, INC.
------------
(Exact name of registrant as specified in its charter)
FLORIDA 000-49720 43-1916702
---------------------------- ---------------- ----------------------
(State or other jurisdiction (Commission file (IRS Employer
of incorporation) number) Identification Number)
9666 Olive Blvd., Suite 310, St. Louis, Missouri 63132
----------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
----------------------------------------------------------
(314) 652-0500
909 South Taylor Avenue, St. Louis, Missouri 63110
--------------------------------------------------------
(Former name or former address if changed since last report)
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT
(a) On July 19, 2004, our independent auditor, Stark Winter Schenkein & Co., LLP
("SWS") of Denver, Colorado, was dismissed. The decision to dismiss SWS was
approved by our board of directors.
The report of SWS dated April 11, 2003 on our consolidated financial statements
for the year ended December 31, 2002 and the period from inception (January 3,
2001) to December 31, 2001, included in our annual report on Form 10-KSB for the
year ended December 31, 2002, was modified for substantial doubt about our
ability to continue as a going concern in light of our loss from operations,
working capital and stockholders' deficiencies and development stage business.
For fiscal year 2003, SWS did not issue an adverse opinion, disclaimer of
opinion or modification or qualification of opinion on our financial statements.
During our two most recent fiscal years and the period from January 1, 2004 to
the date we dismissed SWS, there has been no disagreement with SWS on any matter
of accounting principles or practices, financial statement disclosure, or
auditing scope or procedure, which if not resolved to the satisfaction of SWS,
would have caused it to make reference to the subject matter of the disagreement
in connection with its report.
We authorized SWS to respond fully to any inquiries from our new auditor
concerning any issue relating to our accounting principles or practices or
financial reporting, our financial statements or SWS's audit thereof or audit
opinions thereon.
We provided a copy of the disclosures in this report to SWS. On July 23, 2004,
SWS sent the confirmation letter which is attached hereto as Exhibit 16 and
incorporated by reference herein.
Item 7 Financial Statements and Exhibits
(c) Exhibits
Exhibit No. Description
----------- --------------
16 Confirmation letter dated July 23, 2004 from Stark Winter
Schenkein & Co. to the Securities and Exchange Commission
regarding its dismissal as certifying accountant.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this amended report to be signed on its behalf by the
undersigned hereunto duly authorized.
GenoMed, Inc.
Dated: July 27, 2004 By: /s/ David Moskowitz
------------------------------
Dr. David Moskowitz
Chairman of the Board and
Chief Executive Officer